Drug Trial Radar · NCT05823974
A Study to Assess the Safety and Immune Response of a Vaccine Against Influenza in Healthy Younger and Older Adults
Last checked: Nov 19, 2026Latest source record: Jul 23, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,275
Actual
Start
Apr 27, 2023
Primary completion
Jul 2, 2024
Study completion Dec 18, 2024
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- Collaborators
- CureVac
- First posted
- Apr 21, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to find and confirm the dose and asses the reactogenicity, safety and immune response of GlaxoSmithKline's (GSK) messenger RNA (mRNA)-based multivalent seasonal influenza vaccine (GSK4382276A) candidates administered in healthy younger and older adults (OA).
Conditions
- Influenza, Human
Interventions
F2C22C/DL001ZBiological
Study intervention was administered intramuscularly in Phase 1, at Day 1.
F2B22A/DL001ZBiological
Study intervention was administered intramuscularly in Phase 1, at Day 1.
F2B22B/DL001ZBiological
Study intervention was administered intramuscularly in Phase 1, at Day 1.
F2B22C/DL001ZBiological
Study intervention was administered intramuscularly in Phase 1, at Day 1.
F2B22D/DL001ZBiological
Study intervention was administered intramuscularly in Phase 1, at Day 1.
F2B22E/DL001ZBiological
Study intervention was administered intramuscularly in Phase 1, at Day 1.
F2F22A/DL001ZBiological
Study intervention was administered intramuscularly in Phase 1, at Day 1.
F2F22B/DL001ZBiological
Study intervention was administered intramuscularly in Phase 1, at Day 1.
F2F22C/DL001ZBiological
Study intervention was administered intramuscularly in Phase 1, at Day 1.
F2F22D/DL001ZBiological
Study intervention was administered intramuscularly in Phase 1, at Day 1.
F2F22E/DL001ZBiological
Study intervention was administered intramuscularly in Phase 1, at Day 1.
Control 1Combination product
Control vaccine was administered intramuscularly in Phase 1, at Day 1.
F2F23D/DL001Z-NHBiological
Study intervention was administered intramuscularly in Phase 2, at Day 1.
F2F23A/DL001Z-NHBiological
Study intervention was administered intramuscularly in Phase 2, at Day 1.
F2F23B/DL001Z-NHBiological
Study intervention was administered intramuscularly in Phase 2, at Day 1.
Control 2Combination product
Control vaccine was administered intramuscularly in Phase 2, at Day 1.
F2F23C/DL001Z-NHBiological
Study intervention was administered intramuscularly in Phase 2, at Day 1.
Control 3Combination product
Control vaccine was administered intramuscularly in Phase 2, at Day 1.
F2F22F/DL001ZBiological
Study intervention was administered intramuscularly in Phase 1, at Day 1.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Reporting Any Solicited Administration Site Adverse Events (AEs)Time frame: Day 1 to Day 7
- Number of Participants Reporting Any Solicited Systemic AEsTime frame: Day 1 to Day 7
- Number of Participants Reporting Any Unsolicited AEsTime frame: Day 1 to Day 28
- Number of Participants Reporting Serious Adverse Events (SAEs)Time frame: Day 1 to Day 183
- Number of Participants Reporting AEs of Special Interest (AESIs)Time frame: Day 1 to Day 183
- Number of Participants Reporting Medically Attended Events (MAEs)Time frame: Day 1 to Day 183
- Number of Participants Reporting a Shift From Abnormal Non-clinically Significant and Normal or Missing Laboratory Value on Day 1 to Clinically Significant Abnormal Laboratory Value on Day 8 for Hematology, and Clinical ChemistryTime frame: At Day 8 compared to baseline (Day 1)
- Number of Participants Reporting a Shift From Abnormal Non-clinically Significant and Normal or Missing Laboratory Value on Day 1 to Clinically Significant Abnormal Laboratory Value on Day 29 for Hematology, and Clinical ChemistryTime frame: At Day 29 compared to baseline (Day 1)
- Geometric Mean Titer (GMT) of Antigen 1 Antibody TiterTime frame: At Day 29
- Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29Time frame: From Day 1 (baseline) to Day 29
- Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR)Time frame: From Day 1 to Day 29
- Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR)Time frame: At Day 1
- Percentage of Participants With Antigen 1 Antibody SPRTime frame: At Day 29
- GMT of Antigen 2 Antibody TiterTime frame: At Day 29
- GMI of Antigen 2 Antibody Titer From Day 1 to Day 29Time frame: From Day 1 (baseline) to Day 29
- Percentage of Participants With Antigen 2 Antibody SCRTime frame: From Day 1 to Day 29
Locations
41 sites in 4 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Hialeah, Florida
GSK Investigational Site
Miami, Florida
GSK Investigational Site
Chicago, Illinois
GSK Investigational Site
Valparaiso, Indiana
GSK Investigational Site
Lenexa, Kansas
GSK Investigational Site
Wichita, Kansas
GSK Investigational Site
Lexington, Kentucky
GSK Investigational Site
Boston, Massachusetts
GSK Investigational Site
Dearborn, Michigan
GSK Investigational Site
Papillion, Nebraska
GSK Investigational Site
Rochester, New York
GSK Investigational Site
Syracuse, New York
GSK Investigational Site
Denver, North Carolina
GSK Investigational Site
Greensboro, North Carolina
GSK Investigational Site
Raleigh, North Carolina
GSK Investigational Site
Wilmington, North Carolina
GSK Investigational Site
Dayton, Ohio
GSK Investigational Site
East Greenwich, Rhode Island
GSK Investigational Site
Knoxville, Tennessee
GSK Investigational Site
Fort Worth, Texas
GSK Investigational Site
Houston, Texas
GSK Investigational Site
Tomball, Texas
GSK Investigational Site
Newport News, Virginia
GSK Investigational Site
Norfolk, Virginia
GSK Investigational Site
Antwerp, Belgium
GSK Investigational Site
Edegem, Belgium
GSK Investigational Site
Ghent, Belgium
GSK Investigational Site
Ieper, Belgium
GSK Investigational Site
Kluisbergen, Belgium
GSK Investigational Site
Mechelen, Belgium
GSK Investigational Site
Tielt, Belgium
GSK Investigational Site
Zwalm, Belgium
GSK Investigational Site
Halifax, Nova Scotia, Canada
GSK Investigational Site
Truro, Nova Scotia, Canada
GSK Investigational Site
Chicoutimi, Quebec, Canada
GSK Investigational Site
Québec, Quebec, Canada
GSK Investigational Site
Sherbrooke, Quebec, Canada
GSK Investigational Site
Buffalo, South Africa
GSK Investigational Site
Cape Town, South Africa
GSK Investigational Site
Johannesburg, South Africa
Showing 40 of 41 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.